ADAR1 Funds Hold 8.7% Of Fulcrum Therapeutics Without Seeking To Influence Control

The private funds own 6,648,027 common shares in the rare-disease drug developer, with voting power shared by their adviser and its manager.

Share
ADAR1 Funds Hold 8.7% Of Fulcrum Therapeutics Without Seeking To Influence Control

Private funds managed by investment adviser ADAR1 Capital Management held an 8.7% stake in Fulcrum Therapeutics, which develops drugs for genetically defined rare diseases, as of September 30. ADAR1 reported the position in a passive ownership disclosure filed Monday, certifying that the securities were held without a purpose of changing or influencing Fulcrum's control.

One Holding, Shared Voting Power

The funds directly owned 6,648,027 common shares. ADAR1 and Daniel Schneeberger, its sole manager, each reported indirect beneficial ownership of that same position through the managed funds.

Both reported shared voting power over the full holding and zero sole voting power. Their ownership entries describe the same fund-held shares, so the position belongs to the private funds rather than to Schneeberger personally.

ADAR1 calculated its percentage using 76,381,948 outstanding shares of Fulcrum common stock as of September 30. Fulcrum reported that share count in its quarterly report for the period ended September 30, 2026, filed Thursday.

The reporting persons certified that the shares were bought and held in the ordinary course of business. They also certified that the holding was not connected to a transaction intended to change or influence control.

A Sickle Cell Drug In Development

Fulcrum is a clinical-stage biopharmaceutical company developing small-molecule medicines. Its lead candidate, pociredir, is an oral drug designed to increase fetal hemoglobin—the oxygen-carrying protein normally produced before birth—to treat sickle cell disease, a genetic red-blood-cell disorder.

The company has completed dosing in an early-stage trial in adults. Pociredir remains in clinical development, and Fulcrum has no drug approved for sale.

Fulcrum also searches for cellular drug targets that could alter gene expression and has an early-stage cancer candidate, FTX-6274. It relies on outside manufacturers to produce its drug candidates and operates no manufacturing facilities.

As of February 24, 2026, Fulcrum owned or held licenses to 16 U.S. patents. Its market capitalization was $288 million as of Monday's original report.

Sources

More on Fulcrum Therapeutics

All Fulcrum Therapeutics (FULC) coverage →